CEO Jonathan Peacock told BioWorld Today that the phase III program with drug-device combo Inopulse in pulmonary arterial hypertension (PAH) will start "hopefully in the next few weeks," now that Bellerophon Therapeutics Inc. has in hand a positive analysis of final phase II data with the inhaled nitric-oxide product.